Umut Akova

Umut Akova

Auto-generated profile, based on publicly available information

Umut Akova

Emory University School of Medicine, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2020 in ACS Synthetic Biology
Verified
Journal Article
Closed access
ASAdam D. Silverman
Adam D. Silverman
UAUmut Akova
Umut Akova
KAKhalid K. Alam
Khalid K. Alam
MJMichael C. Jewett
Michael C. Jewett
JLJulius B. Lucks
Julius B. Lucks

1 October 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
Francesco MassariFrancesco Massari
Francesco Massari
MRMatteo Rosellini
Matteo Rosellini
BMBohuslav Melichar
Bohuslav Melichar
EGEnrique Grande
Enrique Grande
MBMaria T. Bourlon
Maria T. Bourlon
MSMatteo Santoni
Matteo Santoni
PURPOSE: Sarcomatoid renal cell carcinoma (sRCC) represents a kidney malignancy with a sarcomatoid component associated with poor prognosis. Immunotherapy (IO)-based combinations demonstrated promising activity in sRCC, yet real-world evidence (RWE) remains limited. We aimed to characterize the clinicopathologic features and outcomes of patients with metastatic sRCC treated with first-line immune-based combinations. PATIENTS AND METHODS: This retrospective analysis from the ARON-1 study included 350 patients with histologically confirmed metastatic sRCC treated with first-line IO + IO, or IO + tyrosine kinase inhibitor across 66 centers in 21 countries (2016-2024). Overall survival (OS) was analyzed using Kaplan-Meier and Cox regression methods. Correlations between 2-year OS and clinical variables were assessed using Pearson's coefficient. RESULTS: After a median follow-up of 19.1 months, median OS was 26.9 months (95% CI, 21.6 to 43.3). OS was longer in males (43.3 v 15.3 months in females; P < .001), in whom underwent nephrectomy (32.3 v 20.7 months; P = .002), and in patients without hepatic (32.3 v 15.3 months; P < .001), without skeletal (41.0 v 20.0 months; P = .007), or without lymph node metastases (43.3 v 24.6 months; P = .037). Median OS varied by International Metastatic RCC Database Consortium (IMDC) risk group: 66.5, 29.4, and 11.7 months in favorable-, intermediate-, and poor-risk patients, respectively ( P < .001). Different IO regimens showed variable outcomes by risk subgroup. Limitations include retrospective design and lack of central pathology review. CONCLUSION: First-line IO-based combinations provide clinically meaningful survival in sRCC, with outcomes affected by sex, metastatic sites, and IMDC risk. This RWE may support a tailored therapeutic approach on the basis of baseline prognostic factors.

1 January 2025 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
AYAhmet Yildirim
Ahmet Yildirim
MMMarcus W. Moses
Marcus W. Moses
MGMargo Gerke
Margo Gerke
YJYash Jani
Yash Jani
JTJillian C. Thompson
Jillian C. Thompson
MBMehmet Bilen
Mehmet Bilen
Non-clear cell renal cell carcinomas (nccRCC) comprise a heterogeneous group of rare malignancies, accounting for approximately 20% of all kidney cancers. Given the rarity of these diverse subsets of RCC, the treatment paradigm for nccRCC is often based on treatment strategies utilized in the management of clear cell renal cell carcinoma (ccRCC), which may not fully address the distinct molecular and genetic drivers unique to nccRCC tumors. However, recent advances in the molecular characterization of nccRCC have led to the identification of new therapeutic targets, resulting in the development of more targeted therapies for nccRCC treatment. Furthermore, the role of molecular characterization of renal tumors is emphasized in the 2022 World Health Organization reclassification of genitourinary tumors, given that delineation of renal tumor subtypes now also relies on genetic markers. In order to highlight this evolving treatment landscape, our review provides a comprehensive summary of recent progress related to the biology and management of nccRCC subtypes.

24 September 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAdam D. Silverman
Adam D. Silverman
UAUmut Akova
Umut Akova
KAKhalid K. Alam
Khalid K. Alam
MJMichael C. Jewett
Michael C. Jewett
JLJulius B. Lucks
Julius B. Lucks
Recent advances in cell-free synthetic biology have spurred the development of in vitro molecular diagnostics that serve as effective alternatives to whole-cell biosensors. However, cell-free sensors for detecting manmade organic water contaminants such as pesticides are sparse, partially because few characterized natural biological sensors can directly detect such pollutants. Here, we present a platform for the cell-free detection of one critical water contaminant, atrazine, by combining a previously characterized cyanuric acid biosensor with a reconstituted atrazine-to-cyanuric acid metabolic pathway composed of several protein-enriched bacterial extracts mixed in a one pot reaction. Our cell-free sensor detects atrazine within an hour of incubation at an activation ratio superior to previously reported whole-cell atrazine sensors. We also show that the response characteristics of the atrazine sensor can be tuned by manipulating the component ratios of the cell-free reaction mixture. Our approach of utilizing multiple metabolic steps, encoded in protein-enriched cell-free extracts, to convert a target of interest into a molecule that can be sensed by a transcription factor is modularly designed, which should enable this work to serve as an effective proof-of-concept for rapid field-deployable detection of complex organic water contaminants.

19 August 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
AAAbdullah Tarik Aslan
Abdullah Tarik Aslan
Lokman H. TanriverdiLokman H. Tanriverdi
Lokman H. Tanriverdi
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
UAUmut Akova
Umut Akova
KKKursat Kutluca
Kursat Kutluca
DPDavid L Paterson
David L Paterson
Background: Asymptomatic bacteriuria (ASB) is generally systematically screened and treated with antibiotics in kidney transplant recipients (KTRs). We aimed to explore the role of antibiotic therapy in management of ASB in KTRs. Methods: Randomized controlled trials conducted through 10 May 2023 were searched on Ovid MEDLINE, Web of Science, PubMed, and Cochrane CENTRAL. We used inverse variance random-effects models for all meta-analyses; for rare outcomes, we used the Mantel-Haenszel method. ROB-2 criteria were used to assess the risk of bias. Results: We identified 4 randomized controlled trials (including 478 participants). Antibiotic therapy, compared with no therapy, nonsignificantly increased the risk of acute pyelonephritis by 19% (relative risk, 1.19 [95% confidence interval (CI)], .72–1.94; I2 = 0%) and that of symptomatic urinary tract infection (UTI) by 18% (1.18 [.78–1.78]; I2 = 28%). The risks of all-cause mortality (relative risk, 1.56 [95% CI, .54–4.52]), graft loss (0.80 [.20–3.19]), graft rejection (0.89 [.46–1.70]), hospital admission due to symptomatic UTI (0.92 [.48–1.76]), symptomatic UTI caused by a multidrug-resistant organism (1.31 [.63–2.74]), Clostridioides difficile diarrhea (0.75 [.23–2.42]), and serious adverse events (1.20 [.75–1.91]) did not differ significantly between groups, nor did the change in serum creatinine level from baseline to the end of the study (mean difference, 0.40 mg/dL [95% CI, −.05 to .85 mg/dL]). No significant differences were demonstrated in any outcomes between antibiotic therapy and no-therapy arms across subgroup and sensitivity analyses. Conclusions: Current evidence does not support routine screening and treatment of posttransplant ASB in KTRs.

4 July 2024 in Surgery
Verified
Journal Article
Closed access
UAUmut Akova
Umut Akova
DWDaniel Wong
Daniel Wong
MGMehmet Gulmez
Mehmet Gulmez
VDVolkan Dogru
Volkan Dogru
EEEren Esen
Eren Esen
FRFeza H. Remzi
Feza H. Remzi